Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients

Multiple studies have shown seemingly unfavorable changes in lipid profiles associated with interleukin‐6 receptor (IL‐6R) antagonists and some other therapies for rheumatoid arthritis. The aim of this study was to assess the real‐world cardiovascular disease (CVD) risk associated with tocilizumab, the first anti–IL‐6R medication approved for the treatment of RA.

• Publication year

  2019

• Venue

  Arthritis care & research

• Publication date

  2019-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.23737PMID 30175897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of algorithms for identifying fatal cardiovascular disease in Medicare claims

  2018cited by this paper
• Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

  2017cited by this paper
• Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study

  2017cited by this paper
• Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

  2016cited by this paper
• Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment

  2016cited by this paper
• Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

  2015cited by this paper
• Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims

  2014cited by this paper
• Linkage of a De‐Identified United States Rheumatoid Arthritis Registry With Administrative Data to Facilitate Comparative Effectiveness Research

  2014cited by this paper
• Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.

  2013cited by this paper
• Identifying newly approved medications in Medicare claims data: a case study using tocilizumab

  2013cited by this paper
• Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity

  2012cited by this paper
• Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

  2012cited by this paper
• Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

  2011cited by this paper
• Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

  2011cited by this paper
• Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

  2008cited by this paper
• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

  2007cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics

  2006influential reference
• Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

  2005cited by this paper
• Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation.

  2005cited by this paper
• Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.

  2004cited by this paper
• British Society for Rheumatology Biologics Register

  2003cited by this paper
• High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

  2001cited by this paper
• Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

  2000cited by this paper
• The New England Journal

  2000cited by this paper
• Checking the Cox model with cumulative sums of martingale-based residuals

  1993cited by this paper
• Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations

  1992cited by this paper

• Frontiers in Rheumatoid Arthritis: Emerging Research and Unmet Needs in Pharmacologic Management.

  2026cites this paper
• Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions

  2025cites this paper
• The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations

  2025influential citation
• Olokizumab therapy and cardiovascular complications in rheumatoid arthritis

  2025cites this paper
• Safety outcomes of tocilizumab and tofacitinib treatment for rheumatoid arthritis: Target trial emulation

  2024cites this paper
• New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review

  2024cites this paper
• Personalized cardiovascular risk assessment in Rheumatoid Arthritis patients using circulating molecular profiles and their modulation by TNFi, IL6Ri, and JAKinibs.

  2024cites this paper
• Dyslipidemia in rheumatoid arthritis: the possible mechanisms

  2023cites this paper
• Dynamics of global longitudinal strain of the left ventricular myocardium and blood biomarker levels in patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors

  2023cites this paper
• Management of cardiovascular disease risk in patients with rheumatoid arthritis

  2023cites this paper
• Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study

  2023cites this paper
• Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab

  2023cites this paper
• Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data

  2023cites this paper
• Using Electronic Health Records and Linked Claims Data to Assess New Medication Use and Primary Nonadherence in Rheumatology Patients

  2023cites this paper
• Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

  2023cites this paper
• Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review

  2023cites this paper
• Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022

  2022cites this paper
• Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis

  2022cites this paper
• Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

  2022cites this paper
• Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis

  2022cites this paper
• Guidance for Administering Biologics for Severe Asthma and Allergic Conditions

  2022cites this paper
• A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases

  2022cites this paper
• Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

  2022cites this paper
• The management of cardiovascular disease risk in patients with rheumatoid arthritis

  2022cites this paper
• A concentração de IL-6 em pacientes com artrite reumatoide tratados com tocilizumabe: revisão integrativa

  2022cites this paper
• Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

  2022cites this paper
• Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis

  2022cites this paper
• Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

  2021cites this paper
• The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review

  2021cites this paper
• Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights

  2021cites this paper
• Cardiovascular effects of approved drugs for rheumatoid arthritis

  2021cites this paper
• Динамика традиционных модифицируемых факторов риска, суммарного сердечно-сосудистого риска и структурных изменений сонных артерий у больных ревматоидным артритом на фоне длительной терапии ингибитором рецепторов интерлейкина-6

  2021cites this paper
• Biomarker and data science as integral part of precision medicine

  2021cites this paper
• Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction

  2021cites this paper
• Adverse Cardiovascular Effects of Anti-COVID-19 Drugs

  2021cites this paper
• Dynamics of traditional modifiable risk factors, total cardiovascular risk, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment

  2021cites this paper
• Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements

  2021cites this paper
• When Randomized Clinical Trials and Real‐World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety

  2020influential citation
• Calcinosis: insights from other calcinoses

  2020cites this paper
• Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke

  2020cites this paper
• Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.

  2020cites this paper
• Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients

  2020cites this paper
• Anti-Inflammatory Therapy in Rheumatoid Arthritis to Improve Cardiovascular Outcome.

  2020cites this paper
• The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

  2020cites this paper
• Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High‐Risk Lesions

  2020cites this paper
• Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

  2020cites this paper
• One year in review 2020: novelties in the treatment of rheumatoid arthritis.

  2020cites this paper
• Inflammation in Heart Failure: JACC State-of-the-Art Review.

  2020cites this paper
• Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs

  2020cites this paper
• Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis

  2020cites this paper
• CHF in Rheumatoid Arthritis Patients

  2020cites this paper
• IL-6R Protective Variant rs7529229 Reduces Interleukin-6 Signaling and Contributes To A Decreased Ischemic Stroke Risk

  2020cites this paper
• The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

  2020cites this paper
• Study of Biologics and Biosimilars

  2019cites this paper
• IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review

  2019cites this paper
• Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial

  2019cites this paper
• The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.

  2019cites this paper
• The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors

  2019cites this paper
• Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.

  2019cites this paper
• Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?

  2019cites this paper
• Useful message in choosing optimal biological agents for patients with autoimmune arthritis.

  2019cites this paper
• Cardiac and vascular complications in rheumatoid arthritis

  2019cites this paper
• Exploring metabolic and inflammatory abnormalities in rheumatoid arthritis patients developing stroke disease: a case-control study using electronic medical record data in northern China

  2019cites this paper
• Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?

  2018cites this paper
• blocking interleukin-6 receptor and interleukin-6 in

  year unknowncites this paper